Chemistry:LY03020

From HandWiki

LY03020 is a dual serotonin 5-HT2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease.[1][2][3] It is taken orally as a controlled-release formulation.[1] The drug is under development by Luye Pharma Group.[1][2][3] As of February 2026, it is in phase 1 clinical trials for both indications.[1][2][3] The chemical structure of LY03020 does not yet appear to have been disclosed.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "LY 03020". 17 February 2026. https://adisinsight.springer.com/drugs/800079474. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on LPM787000048 with Synapse". 9 February 2026. https://synapse.patsnap.com/drug/7aba4f7ed2ed47b8bd4fbdf8ae097827. 
  3. ↑ 3.0 3.1 3.2 "Luye advances dual agonist for schizophrenia, Alzheimer's". 27 March 2026. https://www.bioworld.com/articles/711483-luye-advances-dual-agonist-for-schizophrenia-alzheimers?v=preview. 

Template:TAAR modulators



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LY03020&oldid=4309359"